Lakefront Biotherapeutics to Begin Registrational Trials for Gamgertamig by 2027
Lakefront Biotherapeutics (NASDAQ:LKFT) announced plans to initiate registrational trials in 2027 for its lead T-cell engager, gamgertamig. The therapy is being developed as a short-course treatment with the potential for durable immune reset and will initially target autoimmune diseases such as ITP and AIHA. The company has shifted focus from legacy ex vivo CAR-T programs to four new T-cell engager candidates following its acquisition of Ouro Medicines in March 2026. Gilead Sciences, under a strategic alliance established in 2019, will commercialize gamgertamig and Lakefront expects royalties on sales. Lakefront has completed restructuring efforts from legacy operations that had over $300 million annual spending and more than 650 employees. The company anticipates ending the year with approximately €2 billion in cash, supported by Gilead funding, existing royalties, and tax credits.
Tickers: $GILD
Topics: acquisition financial restructuring registrational trials T-cell engager